Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare the efficacy of 2 different dose levels of AZD2281 versus liposomal doxorubicin in patients with advanced BRCA1 or BRCA2 associated ovarian cancer. This will be assessed by the following: primary variable · progression free survival (PFS) secondary variables · objective response rate (complete response (CR) and partial response (PR)) at various timepoints and overall · overall duration of response · tumour size · CA 125 levels · Overall survival (OS)
Inclusion criteria
- Advanced BRCA1 or BRCA2 associated ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy